Azithramycine

Azithramycine is a lipid of Polyketides (PK) class. Azithramycine is associated with abnormalities such as Respiratory Tract Infections, Pneumonia, Lower respiratory tract infection, Infection and Nonspecific urethritis. The involved functions are known as Lysis, Selection, Genetic, Mutation, Relapse and Adaptation. Azithramycine often locates in Blood, Respiratory System, Genitourinary system, Back and Chest. The associated genes with Azithramycine are Genes, rRNA, Genome, RPL22 gene, OPRM1 gene and tryptic soy broth. The related lipids are Liposomes, Phosphatidylserines, Promega, Lipopolysaccharides and Steroids. The related experimental models are Mouse Model, Knock-out and Tissue Model.

Cross Reference

Introduction

To understand associated biological information of Azithramycine, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Azithramycine?

Azithramycine is suspected in Infection, Pneumonia, Trachoma, Respiratory Tract Infections, Gonorrhea, Infectious disease of lung and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Azithramycine

MeSH term MeSH ID Detail
Toxoplasmosis, Ocular D014126 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Acquired Hyperostosis Syndrome D020083 1 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Syncope, Vasovagal D019462 1 associated lipids
Leishmaniasis, Mucocutaneous D007897 1 associated lipids
Trichiasis D058457 1 associated lipids
Paratyphoid Fever D010284 1 associated lipids
Ectodermal Dysplasia D004476 1 associated lipids
Tooth Erosion D014077 2 associated lipids
Per page 10 20 50 100 | Total 276

PubChem Associated disorders and diseases

What pathways are associated with Azithramycine

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Azithramycine?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Azithramycine?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Azithramycine?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Azithramycine?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Azithramycine?

Mouse Model

Mouse Model are used in the study 'Azithromycin increases in vitro fibronectin production through interactions between macrophages and fibroblasts stimulated with Pseudomonas aeruginosa.' (Cory TJ et al., 2013), Mouse Model are used in the study 'Efficacy of azithromycin, clarithromycin and beta-lactam agents against experimentally induced bronchopneumonia caused by Haemophilus influenzae in mice.' (Miyazaki S et al., 2001), Mouse Model are used in the study 'Oral anti-pneumococcal activity and pharmacokinetic profiling of a novel peptide deformylase inhibitor.' (Gross M et al., 2004), Mouse Model are used in the study 'Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections.' (Bala A et al., 2011) and Mouse Model are used in the study 'Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models.' (Girard D et al., 2005).

Knock-out

Knock-out are used in the study 'Influence of rhlR and lasR on Polymyxin Pharmacodynamics in Pseudomonas aeruginosa and Implications for Quorum Sensing Inhibition with Azithromycin.' (Bulman ZP et al., 2017) and Knock-out are used in the study 'Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants.' (Mulet X et al., 2009).

Tissue Model

Tissue Model are used in the study 'Development of a population pharmacokinetic model characterizing the tissue distribution of azithromycin in healthy subjects.' (Zheng S et al., 2014).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Azithramycine

Download all related citations
Per page 10 20 50 100 | Total 4404
Authors Title Published Journal PubMed Link
Danesi R et al. Comparative distribution of azithromycin in lung tissue of patients given oral daily doses of 500 and 1000 mg. 2003 J. Antimicrob. Chemother. pmid:12654753
Muñoz B et al. Antibiotic dosage in trachoma control programs: height as a surrogate for weight in children. 2003 Invest. Ophthalmol. Vis. Sci. pmid:12657580
Gibb AM et al. Should we offer antibiotic prophylaxis post sexual assault? 2003 Int J STD AIDS pmid:12662387
Ito N and Kudo S [Case of polycystic lung disease with mixed infections due to Aspergillus and Mycobacterium fortuitum successfully treated by AZM]. 2002 Jpn J Antibiot pmid:12664928
Hunter RP et al. Azithromycin metabolite identification in plasma, bile, and tissues of the ball python (Python regius). 2003 J. Vet. Pharmacol. Ther. pmid:12667181
Gerhardt SG et al. Maintenance azithromycin therapy for bronchiolitis obliterans syndrome: results of a pilot study. 2003 Am. J. Respir. Crit. Care Med. pmid:12672648
Schilling F [SAPHO syndrome. A contribution to discussion]. 2003 Wien. Klin. Wochenschr. pmid:12674695
Corbu C et al. [Ocular toxoplasmosis and consecutive complicated cataract]. 2002 Oftalmologia pmid:12677800
Zhou WQ et al. [Clinic efficacy of treating chronic prostatitis caused by Neisseria gonorrhoeae with azithromycin aspartic-acid injection]. 2003 Zhonghua Nan Ke Xue pmid:12680331
Sicklinger M et al. In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto. 2003 J. Clin. Microbiol. pmid:12682190
Karlowsky JA et al. Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). 2003 Clin. Infect. Dis. pmid:12684907
Hamdan II Comparative in vitro investigations of the interaction between some macrolides and Cu(II), Zn(II) and Fe(II). 2003 Pharmazie pmid:12685822
Schachter J and Dawson CR Elimination of blinding trachoma. 2002 Curr. Opin. Infect. Dis. pmid:12686881
Krudsood S et al. A comparative clinical trial of combinations of dihydroartemisinin plus azithromycin and dihydroartemisinin plus mefloquine for treatment of multidrug resistant falciparum malaria. 2002 Southeast Asian J. Trop. Med. Public Health pmid:12693587
Malcolm C and Marrie TJ Antibiotic therapy for ambulatory patients with community-acquired pneumonia in an emergency department setting. 2003 Arch. Intern. Med. pmid:12695270
Seral C et al. Influence of P-glycoprotein and MRP efflux pump inhibitors on the intracellular activity of azithromycin and ciprofloxacin in macrophages infected by Listeria monocytogenes or Staphylococcus aureus. 2003 J. Antimicrob. Chemother. pmid:12697643
Faa AG et al. Scrub typhus in the Torres Strait islands of north Queensland, Australia. 2003 Emerging Infect. Dis. pmid:12702230
Cascio A and Colomba C [Macrolides in the treatment of children with Mediterranean spotted fever]. 2002 Infez Med pmid:12704264
Strle F and Maraspin V Is azithromycin treatment associated with prolongation of the Q-Tc interval? 2002 Wien. Klin. Wochenschr. pmid:12708094
Jacks SS et al. In vitro susceptibilities of Rhodococcus equi and other common equine pathogens to azithromycin, clarithromycin, and 20 other antimicrobials. 2003 Antimicrob. Agents Chemother. pmid:12709351
Hoban DJ et al. Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe. 2003 Eur. J. Clin. Microbiol. Infect. Dis. pmid:12709842
Faber M et al. [Comparative analysis of the effectiveness and costs of azithromycin and cefoperazone treatment of patients during COPD exacerbation]. 2003 Pol. Merkur. Lekarski pmid:12712826
Basualdo W and Arbo A Randomized comparison of azithromycin versus cefixime for treatment of shigellosis in children. 2003 Pediatr. Infect. Dis. J. pmid:12712971
Fernández-Cuenca F et al. In vitro activity of azithromycin in combination with amikacin, ceftazidime, ciprofloxacin or imipenem against clinical isolates of Acinobacter baumannii. 2003 Chemotherapy pmid:12714805
Prata A et al. Efficacy of azithromycin in the treatment of cutaneous leishmaniasis. 2003 Jan-Feb Rev. Soc. Bras. Med. Trop. pmid:12715065
Bird M et al. Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas? 2003 J. Infect. Dis. pmid:12721948
Yoshida H and Kusaba N [Cat scratch disease]. 2003 Nippon Rinsho pmid:12722263
Guchev IA et al. [Prophylaxis of pneumonia occurring outside the hospital in organized groups]. 2003 Voen Med Zh pmid:12722363
Guchev IA et al. [Effect of chemoprophylaxis on pneumonia incidence in organized groups]. 2003 Voen Med Zh pmid:12722514
Maekawa M et al. [Alteration of antibacterial activity of tosufloxacin and various antibacterial agents against Streptococcus pneumoniae]. 2003 Jpn J Antibiot pmid:12723396
Johnson SR et al. Mutations causing in vitro resistance to azithromycin in Neisseria gonorrhoeae. 2003 Int. J. Antimicrob. Agents pmid:12727073
Skerk V et al. Comparative analysis of azithromycin and ciprofloxacin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. 2003 Int. J. Antimicrob. Agents pmid:12727080
Trad O et al. Eradication of Cryptosporidium in four children with acute lymphoblastic leukemia. 2003 J. Trop. Pediatr. pmid:12729299
Llor Vilà C [I'd rather give azithromycin for three days. That way the patient complies]. 2003 Aten Primaria pmid:12735886
Gaynor BD et al. Eliminating trachoma in areas with limited disease. 2003 Emerging Infect. Dis. pmid:12737745
Chanteux H et al. Cell handling, membrane-binding properties, and membrane-penetration modeling approaches of pivampicillin and phthalimidomethylampicillin, two basic esters of ampicillin, in comparison with chloroquine and azithromycin. 2003 Pharm. Res. pmid:12739771
Bachmann K et al. Influence of a 3-day regimen of azithromycin on the disposition kinetics of cyclosporine A in stable renal transplant patients. 2003 Pharmacol. Res. pmid:12742010
Sánchez F et al. Is azithromycin the first-choice macrolide for treatment of community-acquired pneumonia? 2003 Clin. Infect. Dis. pmid:12746768
Castaldo RS et al. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. 2003 Clin Ther pmid:12749513
Frick KD et al. Household willingness to pay for azithromycin treatment for trachoma control in the United Republic of Tanzania. 2003 Bull. World Health Organ. pmid:12751418
Karlowsky JA et al. Susceptibilities to levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis clinical isolates from children: results from 2000-2001 and 2001-2002 TRUST studies in the United States. 2003 Antimicrob. Agents Chemother. pmid:12760850
Yamaguchi H et al. Chlamydia pneumoniae resists antibiotics in lymphocytes. 2003 Antimicrob. Agents Chemother. pmid:12760877
Zhanel GG et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. 2003 J. Antimicrob. Chemother. pmid:12775677
Blandford JM and Gift TL The cost-effectiveness of single-dose azithromycin for treatment of incubating syphilis. 2003 Sex Transm Dis pmid:12782951
Jang D et al. Correlation between culture testing of swabs and ligase chain reaction of first void urine from patients recently treated for Chlamydia trachomatis. 2003 Sex Transm Infect pmid:12794211
Andrews WW et al. Randomized clinical trial of extended spectrum antibiotic prophylaxis with coverage for Ureaplasma urealyticum to reduce post-cesarean delivery endometritis. 2003 Obstet Gynecol pmid:12798523
Engel JN Azithromycin-induced block of elementary body formation in Chlamydia trachomatis. 1992 Antimicrob. Agents Chemother. pmid:1280057
Iakovlev SV and Ukhin SA [Azithromycin: general properties and regimen optimization based on pharmacokinetic and pharmacological parameters]. 2003 Antibiot. Khimioter. pmid:12803047
Peters DH et al. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. 1992 Drugs pmid:1280567
Ito K et al. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. 2003 Drug Metab. Dispos. pmid:12814973
Lynch M et al. Azithromycin treatment coverage in Tanzanian children using community volunteers. 2003 Ophthalmic Epidemiol pmid:12815491
Tyteca D et al. The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: studies on Langmuir-Blodgett monolayers, liposomes and J774 macrophages. 2003 J. Membr. Biol. pmid:12820665
Taylor WR et al. Tolerability of azithromycin as malaria prophylaxis in adults in northeast papua, indonesia. 2003 Antimicrob. Agents Chemother. pmid:12821468
Seral C et al. Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages. 2003 Antimicrob. Agents Chemother. pmid:12821480
Bingen E et al. Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections. 2003 Antimicrob. Agents Chemother. pmid:12821495
Cone LA et al. Delirium in the elderly resulting from azithromycin therapy. 2003 Surg Neurol pmid:12826358
Nigović B and Simunić B Voltammetric assay of azithromycin in pharmaceutical dosage forms. 2003 J Pharm Biomed Anal pmid:12852463
Bhattacharya MK et al. Azithromycin in the treatment of cholera in children. 2003 Acta Paediatr. pmid:12856976
Rush C and Simon MW The effect of amoxicillin-clavulanate, cefixime and azithromycin on normal throat flora in children with group A streptococcal pharyngitis. 2003 Clin Pediatr (Phila) pmid:12862350
Lildholdt T et al. The natural history of recurrent acute tonsillitis and a clinical trial of azithromycin for antibiotic prophylaxis. 2003 Clin Otolaryngol Allied Sci pmid:12871256
Rodvold KA et al. Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. 2003 Antimicrob. Agents Chemother. pmid:12878504
Dunne MW et al. Efficacy of single-dose azithromycin in treatment of acute otitis media in children after a baseline tympanocentesis. 2003 Antimicrob. Agents Chemother. pmid:12878537
Crum NF et al. Halting a pneumococcal pneumonia outbreak among United States Marine Corps trainees. 2003 Am J Prev Med pmid:12880877
Feldman RB et al. Azithromycin monotherapy for patients hospitalized with community-acquired pneumonia: a 31/2-year experience from a veterans affairs hospital. 2003 Arch. Intern. Med. pmid:12885688
Garasiuta EG [Surgical treatment of ulnar and pre-patellar bursitis under ambulatory conditions]. 2000 Voen Med Zh pmid:12886538
Dunne MW et al. Randomized, double-blind study of the clinical efficacy of 3 days of azithromycin compared with co-amoxiclav for the treatment of acute otitis media. 2003 J. Antimicrob. Chemother. pmid:12888586
Falk L et al. Tetracycline treatment does not eradicate Mycoplasma genitalium. 2003 Sex Transm Infect pmid:12902584
Strachan D et al. Is oral azithromycin effective for the treatment of cyclosporine-induced gingival hyperplasia in cardiac transplant recipients? 2003 J Clin Pharm Ther pmid:12911686
Sosa J et al. High percentages of resistance to tetracycline and penicillin and reduced susceptibility to azithromycin characterize the majority of strain types of Neisseria gonorrhoeae isolates in Cuba, 1995-1998. 2003 Sex Transm Dis pmid:12916137
Sahin-Hodoglugil NN et al. A comparison of cost-effectiveness of three protocols for diagnosis and treatment of gonococcal and chlamydial infections in women in Africa. 2003 Sex Transm Dis pmid:12916139
Laming AC and Currie BJ An evaluation of a SAFE-style trachoma control program in central Australia. 2003 Med. J. Aust. pmid:12921100
Ohsaki Y et al. Alterations in penicillin binding protein gene of Streptococcus pneumoniae and their correlation with susceptibility patterns. 2003 Int. J. Antimicrob. Agents pmid:12927954
Zhou LQ et al. [Detection of bacterial 16S rRAN gene in EPS of men with chronic pelvic pain syndrome and its clinical significance]. 2003 Zhonghua Nan Ke Xue pmid:12931366
Batt SL et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. 2003 Antimicrob. Agents Chemother. pmid:12936971
Henry DC et al. Randomized double-blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin-clavulanate regimen for treatment of acute bacterial sinusitis. 2003 Antimicrob. Agents Chemother. pmid:12936972
Sirinavin S et al. Norfloxacin and azithromycin for treatment of nontyphoidal salmonella carriers. 2003 Clin. Infect. Dis. pmid:12942401
Matsuzaki K et al. [Susceptibility of major pathogens of acute pharyngitis and tonsillitis to levofloxacin and other oral antimicrobial drugs]. 2003 Jpn J Antibiot pmid:12942788
DeÄŸerli K et al. Efficacy of azithromycin in a murine toxoplasmosis model, employing a Toxoplasma gondii strain from Turkey. 2003 Acta Trop. pmid:12943976
Favre-Bonté S et al. Biofilm formation by Pseudomonas aeruginosa: role of the C4-HSL cell-to-cell signal and inhibition by azithromycin. 2003 J. Antimicrob. Chemother. pmid:12951348
Rocha JL Correct dose of azithromycin for patients scheduled to undergo dental procedures. 2003 Clin. Infect. Dis. pmid:12955653
Abdelghaffar H et al. Interaction of macrolides and ketolides with the phagocytic cell line PLB-985. 2003 J Chemother pmid:12962363
Sugihara E et al. Macrolide antibiotics directly reduce active oxygen generation by neutrophils in human peripheral blood. 2003 Kurume Med J pmid:12971257
Miguel L and Barbas C LC determination of impurities in azithromycin tablets. 2003 J Pharm Biomed Anal pmid:12972086
Fernández Cuenca F et al. [In vitro activity of azithromycin against clinical isolates of Acinetobacter baumannii]. 2003 Rev Esp Quimioter pmid:12973458
Huang C et al. Susceptibility of mixed infection of Ureaplasma Urealyticum and Mycoplasma Hominis to seven antimicrobial agents and comparison with that of Ureaplasma Urealyticum infection. 2003 J. Huazhong Univ. Sci. Technol. Med. Sci. pmid:12973952
Neu HC New macrolide antibiotics: azithromycin and clarithromycin. 1992 Ann. Intern. Med. pmid:1310839
O'Connor CM et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. 2003 JAMA pmid:13129985
Massarotti EM et al. Treatment of early Lyme disease. 1992 Am. J. Med. pmid:1313637
Pruul H and McDonald PJ Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum. 1992 Antimicrob. Agents Chemother. pmid:1317141
Brown BA et al. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. 1992 Antimicrob. Agents Chemother. pmid:1317144
Kobrehel G et al. Synthesis and antibacterial activity of O-methylazithromycin derivatives. 1992 J. Antibiot. pmid:1317368
Welsh LE et al. In vitro evaluation of activities of azithromycin, erythromycin, and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1318677
Bahal N and Nahata MC The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. 1992 Ann Pharmacother pmid:1318761
Drew RH and Gallis HA Azithromycin--spectrum of activity, pharmacokinetics, and clinical applications. 1992 Pharmacotherapy pmid:1319048
Chave JP et al. Once-a-week azithromycin in AIDS patients: tolerability, kinetics, and effects on zidovudine disposition. 1992 Antimicrob. Agents Chemother. pmid:1324635
Derouin F et al. Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. 1992 Antimicrob. Agents Chemother. pmid:1324642
Vallée E et al. Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. 1992 Antimicrob. Agents Chemother. pmid:1324644
Mertens JC et al. Double-blind randomized study comparing the efficacies and safeties of a short (3-day) course of azithromycin and a 5-day course of amoxicillin in patients with acute exacerbations of chronic bronchitis. 1992 Antimicrob. Agents Chemother. pmid:1324645
Hammerschlag MR et al. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. 1992 Antimicrob. Agents Chemother. pmid:1324650
Paulsen P et al. Influence of azithromycin and other macrolides on the intracellular killing of Staphylococcus aureus by human polymorphonuclear leucocytes of healthy donors and a patient with Chédiak-Higashi syndrome. 1992 Chemotherapy pmid:1324831